Rezolute Inc. Common Stock (NV)
Exchange: NASDAQ
Symbol: RZLT
SEC CIK: 0001509261
Phone: 650-847-1919
201 REDWOOD SHORES PARKWAY, SUITE 315
REDWOOD CITY CA 94065
CEO: Nevan Elam
|
Price when page updated: 0.7568 Date: 2023-12-01
Company Website:
www.rezolutebio.com
|
_Description: Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor, which is staged to transition into clinical development for the treatment of diabetic macular edema.
IPO YEAR:
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
29988405.00
|
Beta:
0.395463082601092
|
52 Week High:
17.47
|
52 Week Low:
4.01
|
52 Week Change:
-0.6843537414965987
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
15440250
|
Dividend Rate:
0
|
Dividend Yield:
2.43%
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
25 Oct 2022
|
Float:
0
|
return on Equity:
6.20%
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
$9.133B
|
ttmEPS:
0
|
Revenue:
$65.287B
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
81.40%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
0.10%
|
Return on Assets:
2.80%
|
Return on Capital:
|
Profit Margin:
6.80%
|
Price to Sales:
2.06
|
Price To Book:
1.86
|
Short Ratio:
1.36
|
PE Ratio:
0
|
Employees:
23
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__Rezolute Inc. Common Stock (NV) [ RZLT ].
__Note: Some Links might not have information for the company.
|
|
